InVivo Therapeutics Stock Price, News & Analysis (NASDAQ:NVIV) $0.71 -0.02 (-2.74%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$0.65▼$0.7450-Day Range$0.60▼$1.1952-Week Range$0.60▼$2.80Volume27,885 shsAverage Volume48,191 shsMarket Capitalization$2.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media About InVivo Therapeutics Stock (NASDAQ:NVIV)InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.Read More NVIV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVIV Stock News HeadlinesDecember 2, 2023 | americanbankingnews.comInVivo Therapeutics (NASDAQ:NVIV) Research Coverage Started at StockNews.comNovember 10, 2023 | morningstar.comInVivo Therapeutics Holdings Corp NVIVDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. June 22, 2023 | marketwatch.comSpinal Cord Trauma Treatment Market Analysis: Examining Trends and Forecasting Revenue Growth with an estimated CAGR 6.2% from 2023-2030May 1, 2023 | benzinga.comRing Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate StrategyMarch 17, 2023 | finance.yahoo.comWhy InVivo Therapeutics Shares Are Plunging TodayMarch 10, 2023 | msn.comInVivo seeks longer-term control in Casino-Teract retail tie-upMarch 10, 2023 | msn.comWhy Barnes & Noble Education Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving PremarketDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. March 10, 2023 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.66%March 9, 2023 | msn.comWhy JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionMarch 9, 2023 | markets.businessinsider.comInVivo : INSPIRE 2.0 Study In Acute Spinal Cord Injury Fails To Meet Primary EndpointMarch 9, 2023 | msn.comInVivo to evaluate strategic options as trial for spinal injury device failsMarch 9, 2023 | marketwatch.comInVivo Therapeutics Shares Hit 52-Week Low After Study Misses Primary EndpointMarch 9, 2023 | marketwatch.comInVivo Therapeutics Study for Neuro-Spinal Scaffold Misses Primary EndpointMarch 9, 2023 | finance.yahoo.comInVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord InjuryJanuary 11, 2023 | benzinga.comInVivo Therapeutics Hldg Stock (NASDAQ:NVIV), Quotes and News SummaryOctober 11, 2022 | finance.yahoo.comInVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq RulesOctober 10, 2022 | marketwatch.comInVivo Therapeutics Shares Continue Friday's Fall, Hit All-Time Intraday LowOctober 7, 2022 | seekingalpha.comInVivo Therapeutics dips 24% on $9M direct and private placement offeringsOctober 7, 2022 | marketwatch.comInVivo Therapeutics Stock Drops on $9 Million OfferingOctober 7, 2022 | investorplace.comWhy Is InVivo Therapeutics (NVIV) Stock Down 34% Today?October 7, 2022 | finance.yahoo.comInVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq RulesSeptember 9, 2022 | finance.yahoo.comInVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment ConferenceAugust 28, 2022 | uk.finance.yahoo.comInVivo Therapeutics Holdings Corp. (NVIV)July 13, 2022 | finance.yahoo.comInVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General CounselJune 8, 2022 | finance.yahoo.comInVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed NeurosurgerySee More Headlines Receive NVIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVIV CUSIPN/A CIK1292519 Webwww.invivotherapeutics.com Phone(617) 863-5500FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-75.04% Return on Assets-65.01% Debt Debt-to-Equity RatioN/A Current Ratio14.30 Quick Ratio14.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.48 per share Price / Book0.11Miscellaneous Outstanding Shares3,110,000Free Float3,085,000Market Cap$2.21 million OptionableNot Optionable Beta0.74 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Richard M. Toselli (Age 65)President, CEO, Chief Medical Officer & Director Comp: $825.2kMr. Richard C. Christopher (Age 53)CFO & Treasurer Comp: $537.82kMs. Heather M. Hamel J.D. (Age 33)Chief Legal Officer & General Counsel Comp: $446.96kDr. Robert S. Langer Jr. (Age 74)Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Joseph Philip Vacanti M.D. (Age 74)Co-Founder Key CompetitorsDermata TherapeuticsNASDAQ:DRMACohBarNASDAQ:CWBRAdial PharmaceuticalsNASDAQ:ADIL9 Meters BiopharmaNASDAQ:NMTREvofem BiosciencesNASDAQ:EVFMView All Competitors NVIV Stock Analysis - Frequently Asked Questions How have NVIV shares performed in 2023? InVivo Therapeutics' stock was trading at $2.35 at the start of the year. Since then, NVIV shares have decreased by 69.8% and is now trading at $0.71. View the best growth stocks for 2023 here. Are investors shorting InVivo Therapeutics? InVivo Therapeutics saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 1,000 shares, a decline of 88.2% from the October 31st total of 8,500 shares. Based on an average daily volume of 12,800 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company's shares are short sold. View InVivo Therapeutics' Short Interest. When is InVivo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024. View our NVIV earnings forecast. How were InVivo Therapeutics' earnings last quarter? InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) posted its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.87) EPS for the quarter. When did InVivo Therapeutics' stock split? InVivo Therapeutics shares reverse split on the morning of Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of InVivo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other InVivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), iShares Preferred and Income Securities ETF (PFF), Verastem (VSTM), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), Apollo Investment (AINV), IVERIC bio (OPHT), OPKO Health (OPK) and Cardiff Oncology (TROV). How do I buy shares of InVivo Therapeutics? Shares of NVIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:NVIV) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InVivo Therapeutics Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.